Skip to content
Triangle logo TriangleGet started
← Liver Neoplasm

NCT00957424 · STUDY IN CONTEXT

Acceptability of Less Harmful Alternatives to Cigarettes

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs)

Source null

→

primary · POSTED

Number of Participants Willing to Try HRPs

Source null

→

primary · POSTED

Number of Participants That Completed 1-week Trial

Source null

→

primary · POSTED

Number of Participants Willing to Continue With Preferred HRP

Those who completed one-week multiple product sampling

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-liver-neoplasm
nct id
NCT00957424
trial label
Acceptability of Less Harmful Alternatives to Cigarettes
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
4
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    outcome key
    om-0000
    source section id
    NCT00957424-om-0000
    source outcome index
    0
    endpoint
    Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs)
    endpoint definition
    Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs)
    time origin
    Baseline
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    outcome key
    om-0001
    source section id
    NCT00957424-om-0001
    source outcome index
    1
    endpoint
    Number of Participants Willing to Try HRPs
    endpoint definition
    Number of Participants Willing to Try HRPs
    time origin
    Baseline
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    outcome key
    om-0002
    source section id
    NCT00957424-om-0002
    source outcome index
    2
    endpoint
    Number of Participants That Completed 1-week Trial
    endpoint definition
    Number of Participants That Completed 1-week Trial
    time origin
    One week
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    outcome key
    om-0003
    source section id
    NCT00957424-om-0003
    source outcome index
    3
    endpoint
    Number of Participants Willing to Continue With Preferred HRP
    endpoint definition
    Number of Participants Willing to Continue With Preferred HRP
    time origin
    1 week follow up
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Those who completed one-week multiple product sampling
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Overall
    regimen
    Single-armed study
    analyzed count
    67
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00957424-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Overall
    regimen
    Single-armed study
    analyzed count
    67
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00957424-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Overall
    regimen
    Single-armed study
    analyzed count
    67
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00957424-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Overall
    regimen
    Single-armed study
    analyzed count
    50
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00957424-om-0003#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-liver-neoplasm
    nct id
    NCT00957424
    harm key
    EG000
    source section id
    NCT00957424-ae
    event group key
    EG000
    event group label
    Overall
    serious affected
    0
    serious at risk
    59
    other affected
    0
    other at risk
    59
    frequency threshold
    0
    collection period
    Collected over 2 weeks while participants were using tobacco products
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice